{"id":2432,"date":"2026-02-18T15:10:06","date_gmt":"2026-02-18T14:10:06","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/yeni-nihai-veriler-atezolizumab-ile-immuenoterapi-tekrarlayan-yumurtalik-kanserinde-ek-fayda-saglamiyor\/"},"modified":"2026-03-05T11:57:34","modified_gmt":"2026-03-05T10:57:34","slug":"yeni-nihai-veriler-atezolizumab-ile-immuenoterapi-tekrarlayan-yumurtalik-kanserinde-ek-fayda-saglamiyor","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/yeni-nihai-veriler-atezolizumab-ile-immuenoterapi-tekrarlayan-yumurtalik-kanserinde-ek-fayda-saglamiyor\/","title":{"rendered":"Yeni nihai veriler: Atezolizumab ile imm\u00fcnoterapi, tekrarlayan yumurtal\u0131k kanserinde ek fayda sa\u011flam\u0131yor"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2432\" class=\"elementor elementor-2432 elementor-2383\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e438c86 e-flex e-con-boxed e-con e-parent\" data-id=\"e438c86\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2cf51b7 elementor-widget elementor-widget-heading\" data-id=\"2cf51b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>Yeni nihai veriler:<\/strong> Atezolizumab ile imm\u00fcnoterapi, tekrarlayan yumurtal\u0131k kanserinde ek fayda sa\u011flam\u0131yor<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-070f551 elementor-widget elementor-widget-text-editor\" data-id=\"070f551\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p data-start=\"321\" data-end=\"838\"><strong data-start=\"368\" data-end=\"398\">AGO-OVAR 2.29 (ENGOT-ov34) <\/strong>\u00e7al\u0131\u015fmas\u0131n\u0131n nihai sonu\u00e7lar\u0131 Aral\u0131k 2025&#8217;te yay\u0131nlanm\u0131\u015ft\u0131r.<\/p><p data-start=\"321\" data-end=\"838\">Bu b\u00fcy\u00fck uluslararas\u0131 faz III \u00e7al\u0131\u015fmada, <strong data-start=\"501\" data-end=\"516\">bevacizumab<\/strong> ve platin bazl\u0131 olmayan kemoterapi ile birlikte imm\u00fcnoterapi ilac\u0131 <strong data-start=\"471\" data-end=\"487\">atezolizumab\u0131n<\/strong> ek olarak uygulanmas\u0131n\u0131n tekrarlayan <strong data-start=\"598\" data-end=\"632\">yumurtal\u0131k kanseri<\/strong> olan hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 uzat\u0131p uzatamayaca\u011f\u0131 ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r.<br data-start=\"649\" data-end=\"652\">Bu kanser t\u00fcr\u00fc, platin bazl\u0131 kemoterapi uygulanm\u0131\u015f olsa bile tekrarlar ve tedavisi \u00f6zellikle zor olarak kabul edilir.<\/p><p data-start=\"840\" data-end=\"1062\">\u00c7al\u0131\u015fmada toplam 574 hasta randomize edilmi\u015f ve standart tedavi (kemoterapi + bevacizumab + plasebo) ya da ek olarak atezolizumab alm\u0131\u015ft\u0131r.<\/p><h3 data-start=\"1064\" data-end=\"1102\"><strong>\u00c7al\u0131\u015fma ne g\u00f6sterdi?<\/strong><\/h3><p data-start=\"1103\" data-end=\"1195\">\u27a1\ufe0f Atezolizumab ilavesi ile <strong data-start=\"1106\" data-end=\"1143\">net bir sa\u011fkal\u0131m faydas\u0131<\/strong> bulunmam\u0131\u015ft\u0131r:<\/p><ul data-start=\"1196\" data-end=\"1809\"><li data-start=\"1196\" data-end=\"1504\"><p data-start=\"1198\" data-end=\"1504\">Ortanca <strong data-start=\"1210\" data-end=\"1239\">genel sa\u011fkal\u0131m (OS<\/strong> ) atezolizumab ile yakla\u015f\u0131k <strong data-start=\"1270\" data-end=\"1286\">14,2 ay<\/strong> ve kontrol grubunda <strong data-start=\"1317\" data-end=\"1333\">13,0 ayd\u0131<\/strong> &#8211; bu fark <strong data-start=\"1359\" data-end=\"1392\">istatistiksel olarak anlaml\u0131 de\u011fildi<\/strong>, yani g\u00fcvenilir bir avantajdan s\u00f6z etmek i\u00e7in yeterince a\u00e7\u0131k de\u011fildi.<\/p><\/li><li data-start=\"1505\" data-end=\"1809\"><p data-start=\"1507\" data-end=\"1809\">Medyan <strong data-start=\"1519\" data-end=\"1556\">progresyonsuz sa\u011fkal\u0131m (PFS)<\/strong> &#8211; yani t\u00fcm\u00f6r\u00fcn tekrar b\u00fcy\u00fcmedi\u011fi s\u00fcre &#8211; kontrol grubundaki <strong data-start=\"1665\" data-end=\"1680\">6,7 aya<\/strong> k\u0131yasla atezolizumab ile hemen hemen ayn\u0131yd\u0131 ve istatistiksel olarak kan\u0131tlanm\u0131\u015f bir avantaj da yoktu.<\/p><\/li><\/ul><p data-start=\"1811\" data-end=\"2076\">\ud83d\udca1 Bu, atezolizumab ile imm\u00fcnoterapinin, bevacizumab ve kemoterapiye ek olarak verildi\u011finde bu \u00e7al\u0131\u015fmada hastal\u0131k kontrol\u00fcnde net bir iyile\u015fmeye veya ya\u015fam s\u00fcresinin uzamas\u0131na yol a\u00e7mad\u0131\u011f\u0131 anlam\u0131na gelir.<\/p><h3 data-start=\"2078\" data-end=\"2125\"><strong data-start=\"2083\" data-end=\"2123\">Peki ya yan etkiler?<\/strong><\/h3><p data-start=\"2126\" data-end=\"2409\">Ciddi yan etkiler (derece \u2265 3) atezolizumab alan hastalarda biraz daha s\u0131k g\u00f6r\u00fclm\u00fc\u015ft\u00fcr (%72&#8217;ye kar\u015f\u0131 %69), ancak genel olarak g\u00fcvenlik profili tek <strong data-start=\"2290\" data-end=\"2370\">tek ila\u00e7lar i\u00e7in bilinenlerle kar\u015f\u0131la\u015ft\u0131r\u0131labilir<\/strong> d\u00fczeydedir.<\/p><h3 data-start=\"2411\" data-end=\"2476\"><strong data-start=\"2416\" data-end=\"2474\">PD-L1 durumuna ba\u011fl\u0131 olarak bir fark g\u00f6zlendi mi?<\/strong><\/h3><p data-start=\"2477\" data-end=\"2805\">\u00c7al\u0131\u015fmada ayr\u0131ca PD-L1-pozitif t\u00fcm\u00f6rl\u00fc hastalar\u0131n (imm\u00fcnoterapiye daha iyi yan\u0131t vermenin olas\u0131 bir g\u00f6stergesi) atezolizumabdan daha fazla fayda g\u00f6r\u00fcp g\u00f6rmedi\u011fi de ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Durum b\u00f6yle de\u011fildi &#8211; t\u00fcm\u00f6r\u00fcn PD-L1-pozitif veya negatif olmas\u0131na bak\u0131lmaks\u0131z\u0131n sonu\u00e7lar benzerdi. <br><br><\/p><p data-start=\"3203\" data-end=\"3462\"><strong data-start=\"3206\" data-end=\"3241\">Ara\u015ft\u0131rmaya \u00f6nemli katk\u0131<\/strong><br data-start=\"3241\" data-end=\"3244\">Bu \u00f6zel sonu\u00e7lar olumsuz olsa bile, <strong data-start=\"3360\" data-end=\"3419\">hangi tedavilerin hangi durumlarda ger\u00e7ekten yard\u0131mc\u0131<\/strong> oldu\u011funu ve hala yeni yakla\u015f\u0131mlara ihtiya\u00e7 duydu\u011fumuzu tam olarak anlamak i\u00e7in bu t\u00fcr b\u00fcy\u00fck \u00e7al\u0131\u015fmalar \u00f6nemlidir.<\/p><p data-start=\"3464\" data-end=\"3827\">\ud83d\udca1 <strong data-start=\"3467\" data-end=\"3500\">Standartlar de\u011fi\u015fmeden kal\u0131r<\/strong><br data-start=\"3500\" data-end=\"3503\">Platine diren\u00e7li n\u00fcks\u00fc olan hastalar i\u00e7in, bevacizumab ile kemoterapi veya di\u011fer etkili kombinasyonlar gibi yerle\u015fik tedavi se\u00e7enekleri \u015fu anda \u00f6nerilen standart olmaya devam etmektedir. Atezolizumab gibi imm\u00fcnoterapi \u015fu anda bu ortamda standart tedaviden <strong data-start=\"3760\" data-end=\"3792\">daha etkili de\u011fildir<\/strong>. <br><br><\/p><p><span style=\"color: #29b8ce;\"><strong>Kaynak:<\/strong> <\/span><a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO-25-01210\" target=\"_blank\" rel=\"noopener\">ASCO yay\u0131n\u0131<\/a> (makale \u0130ngilizce&#8217;dir)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Yeni nihai veriler: Atezolizumab ile imm\u00fcnoterapi, tekrarlayan yumurtal\u0131k kanserinde ek fayda sa\u011flam\u0131yor AGO-OVAR 2.29 (ENGOT-ov34) \u00e7al\u0131\u015fmas\u0131n\u0131n nihai sonu\u00e7lar\u0131 Aral\u0131k 2025&#8217;te yay\u0131nlanm\u0131\u015ft\u0131r. Bu b\u00fcy\u00fck uluslararas\u0131 faz III \u00e7al\u0131\u015fmada, bevacizumab ve platin bazl\u0131 olmayan kemoterapi ile birlikte imm\u00fcnoterapi ilac\u0131 atezolizumab\u0131n ek olarak uygulanmas\u0131n\u0131n tekrarlayan yumurtal\u0131k kanseri olan hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 uzat\u0131p uzatamayaca\u011f\u0131 ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r.Bu kanser t\u00fcr\u00fc, platin bazl\u0131 kemoterapi [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":1864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"class_list":["post-2432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-haberler"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/2432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=2432"}],"version-history":[{"count":5,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/2432\/revisions"}],"predecessor-version":[{"id":2447,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/2432\/revisions\/2447"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media\/1864"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=2432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=2432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=2432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}